21/10/2016ABLYNX ANNOUNCES WARRANT EXERCISE
20/10/2016ABLYNX OUTLINES NEXT STEPS FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS
12/10/2016ABLYNX ANNOUNCES SECOND EXTENSION OF ITS ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC.
11/10/2016FMR LLC ANNOUNCE 9.22% SHAREHOLDING IN ABLYNX
10/10/2016ABLYNX INITIATES A PHASE III FOLLOW-UP STUDY OF ITS FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, FOR THE TREATMENT OF ACQUIRED TTP
29/09/2016ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP
15/09/2016ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC.
06/09/2016ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM GAM HOLDING AG, GAM INTERNATIONAL MANAGEMENT LIMITED AND TAUBE HODSON STONEX PARTNERS LLP
25/08/2016ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE
17/08/2016ABLYNX WILL ANNOUNCE ITS 2016 HALF YEAR RESULTS WITH WEBCAST ON 25 AUGUST 2016
12/08/2016ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V.
09/08/2016ABLYNX REPORTS COMPELLING TOPLINE PHASE IIb STUDY RESULTS WITH ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, IN RA PATIENTS, CONFIRMING ITS BEST-IN-CLASS POTENTIAL
04/08/2016BANK OF AMERICA CORPORATION ANNOUNCE 5.24% SHAREHOLDING IN ABLYNX
20/07/2016ABLYNX ANNOUNCES WARRANT EXERCISE
07/07/2016ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), AS A MONOTHERAPY IN RA
16/06/2016CORRECTION TRANSPARENCY NOTIFICATION - ADRIANUS VAN HERK ANNOUNCES 3.02% SHAREHOLDING IN ABLYNX
16/06/2016VAN HERK INVESTMENTS ANNOUNCE 3.02% SHAREHOLDING IN ABLYNX
14/06/2016PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
10/06/2016PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
03/06/2016ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES HEALTHCARE CONFERENCE 2016
01/06/2016ABLYNX SUCCESSFULLY RAISES €74.2 MILLION
The following information does not constitute an offer of, or solicitation of an offer to purchase or subscribe for, securities of the Issuer and there shall not be any sale of securities in any jurisdiction where such an offer is unlawful prior to its registration or qualification under the laws of such jurisdiction. Likewise, the following information does not constitute an offer or solicitation of an offer to purchase or subscribe for the securities to any person who may not by law receive such an offer or solicitation. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any state or jurisdiction in the United States and may not be offered, sold, resold, transferred or delivered, directly or indirectly within the United States except pursuant to an applicable exemption from the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or jurisdiction of the United States. The issuer of the securities has not registered, and does not intend to register, any portion of the offering in the United States, and does not intend to conduct a public offering of securities in the United States, or an offering in Canada, Australia or Japan, or to any national, resident or citizen of Canada, Australia or Japan. The following information, nor any part or copy thereof, may be brought or sent in or directly or indirectly distributed in the United States, Australia, Canada or Japan or elsewhere outside of Belgium. Failure to observe these restrictions may constitute a violation of Australian, Canadian, Japanese or US federal securities law. The distribution of this information in other jurisdictions may be restricted by law and persons into whose possession this information comes should inform themselves about, and observe, any such restrictions.
No money, payment or other forms of consideration may be requested via this website, or the information it contains, in any jurisdiction where such an offer is unlawful or if the offer is made to any other person who may not by law receive such an offer or solicitation. Payment, consideration or money sent in response to this website or the information it contains will not be accepted.
By clicking on the box to indicate acceptance below, you agree that you have read and will respect the above warnings and you warrant that (i) you are not domiciled in the United States and are not accessing this information from the United States; (ii) you do not reside in Australia or Canada; (iii) you do not reside and are not domiciled in Japan and (iv) you do not reside and you are not domiciled in any other jurisdiction where the distribution of this information is not allowed legally and that you are not a person who may not receive this information, and that you agree not to send any information from this website to any person whomsoever residing or domiciled outside of Belgium.
01/06/2016ABLYNX TO RAISE CAPITAL THROUGH A PRIVATE PLACEMENT OF NEW SHARES
26/05/2016ABLYNX TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN STUDY WITH CAPLACIZUMAB IN ACQUIRED TTP PATIENTS AT THE 21st CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
13/05/2016PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
12/05/2016ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2016 AND PROVIDES BUSINESS UPDATE YEAR-TO-DATE
03/05/2016ABLYNX REPORTS POSITIVE TOP LINE RESULTS FOR ITS INHALED ANTI-RSV NANOBODY (ALX-0171) IN A PHASE I/IIa STUDY IN INFANTS HOSPITALISED WITH AN RSV INFECTION
29/04/2016ABLYNX ANNOUNCES MILESTONE IN DRUG DISCOVERY COLLABORATION
22/04/2016ABLYNX ANNOUNCES WARRANT EXERCISE
21/04/2016ABLYNX TO RECEIVE AN €8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS A PHASE I STUDY WITH AN ANTI-CX3CR1 NANOBODY
22/03/2016ABLYNX ANNOUNCES WARRANT EXERCISE
14/03/2016PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
07/03/2016PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
25/02/2016ABLYNX ANNOUNCES 2015 FULL YEAR RESULTS
23/02/2016ABLYNX ANNOUNCES WARRANT EXERCISE
18/02/2016ABLYNX WILL ANNOUNCE ITS 2015 FULL YEAR RESULTS WITH WEBCAST ON 25 FEBRUARY 2016
11/02/2016NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES ABLYNX'S PHASE II TITAN STUDY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP
29/01/2016ABLYNX TO RECEIVE €8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS FIRST PATIENT STUDY WITH A BI-SPECIFIC NANOBODY IN ONCOLOGY
21/01/2016ABLYNX ANNOUNCES WARRANT EXERCISE
18/01/2016PERCEPTIVE ADVISORS LLC ANNOUNCE 5.06% SHAREHOLDING IN ABLYNX
07/01/2016ABLYNX TO PRESENT AT THE 34th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
05/01/2016PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Click the button below to subscribe to the Ablynx news service